These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29660782)

  • 1. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
    Sasaki T; Sugawara M; Fukuda M
    J Diabetes Investig; 2019 Jan; 10(1):108-117. PubMed ID: 29660782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study.
    Bouchi R; Terashima M; Sasahara Y; Asakawa M; Fukuda T; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Cardiovasc Diabetol; 2017 Mar; 16(1):32. PubMed ID: 28253918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.
    Jinnouchi H; Nozaki K; Watase H; Omiya H; Sakai S; Samukawa Y
    Adv Ther; 2016 Mar; 33(3):460-79. PubMed ID: 26846284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
    Yabe D; Iwasaki M; Kuwata H; Haraguchi T; Hamamoto Y; Kurose T; Sumita K; Yamazato H; Kanada S; Seino Y
    Diabetes Obes Metab; 2017 May; 19(5):739-743. PubMed ID: 27990776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
    Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
    J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
    Ejiri K; Miyoshi T; Kihara H; Hata Y; Nagano T; Takaishi A; Toda H; Nanba S; Nakamura Y; Akagi S; Sakuragi S; Minagawa T; Kawai Y; Nishii N; Fuke S; Yoshikawa M; Nakamura K; Ito H;
    J Am Heart Assoc; 2020 Aug; 9(16):e015103. PubMed ID: 32805185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.
    Samukawa Y; Omiya H; Watase H; Nozaki K; Sakai S; Nishimura R
    Adv Ther; 2016 Jul; 33(7):1215-30. PubMed ID: 27255763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction.
    Tsukagoshi-Yamaguchi A; Koshizaka M; Ishibashi R; Ishikawa K; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Terayama R; Hattori A; Takemoto M; Ouchi Y; Maezawa Y; Yokote K;
    Pharmacotherapy; 2023 Dec; 43(12):1317-1326. PubMed ID: 37772313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.
    Cai X; Ji L; Chen Y; Yang W; Zhou L; Han X; Zhang S; Ji L
    J Diabetes Investig; 2017 Jul; 8(4):510-517. PubMed ID: 28106956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Arase Y; Shiraishi K; Anzai K; Sato H; Teramura E; Tsuruya K; Hirose S; Deguchi R; Toyoda M; Mine T; Kagawa T
    Clin Drug Investig; 2019 Jul; 39(7):631-641. PubMed ID: 30993553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease.
    Inoue M; Hayashi A; Taguchi T; Arai R; Sasaki S; Takano K; Inoue Y; Shichiri M
    J Diabetes Investig; 2019 Jul; 10(4):1004-1011. PubMed ID: 30461221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected metabolic effects of sodium-glucose cotransporter 2 inhibitors.
    Drueke TB; Massy ZA
    Kidney Int; 2024 Jul; 106(1):12-15. PubMed ID: 38775770
    [No Abstract]   [Full Text] [Related]  

  • 13. Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, reverses cerebrovascular dysfunction and cognitive impairments in 18-mo-old diabetic animals.
    Wang S; Jiao F; Border JJ; Fang X; Crumpler RF; Liu Y; Zhang H; Jefferson J; Guo Y; Elliott PS; Thomas KN; Strong LB; Urvina AH; Zheng B; Rijal A; Smith SV; Yu H; Roman RJ; Fan F
    Am J Physiol Heart Circ Physiol; 2022 Feb; 322(2):H246-H259. PubMed ID: 34951541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
    Yamazaki D; Konishi Y; Morikawa T; Kobara H; Masaki T; Hitomi H; Osafune K; Nakano D; Kittikulsuth W; Nishiyama A
    J Diabetes Investig; 2020 Jul; 11(4):834-843. PubMed ID: 31880858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study.
    Pitsiava S; Dimakopoulos G; Tsimihodimos V; Kotsa K; Koufakis T
    Expert Opin Pharmacother; 2024 Jun; 25(8):1095-1104. PubMed ID: 38822807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of combination of change in visceral fat and thigh muscle mass on the development of type 2 diabetes.
    Han SJ; Kim SK; Fujimoto WY; Kahn SE; Leonetti DL; Boyko EJ
    Diabetes Res Clin Pract; 2017 Dec; 134():131-138. PubMed ID: 29032053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes.
    Zhu J; Wilding JPH
    Curr Atheroscler Rep; 2024 Jan; 26(1):1-10. PubMed ID: 38148417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved.
    Afsar B; Afsar RE
    Clin Nutr; 2023 Dec; 42(12):2338-2352. PubMed ID: 37862820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review.
    Jahangiri S; Malek M; Kalra S; Khamseh ME
    Diabetes Ther; 2023 Dec; 14(12):2015-2030. PubMed ID: 37837581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: a case report.
    Ishizuka T; Tokuyama Y; Horie A; Kanatsuka A
    Diabetol Int; 2021 Jan; 12(1):130-134. PubMed ID: 33479589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.